Prostate Cancer Clinical Trial
— OPTIMABIOfficial title:
Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer
Verified date | January 2022 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test whether a dose escalation up to 2000 mg per day of abiraterone acetate is feasible and lead to disease stabilization in castration-resistant metastatic prostate cancer patients who experience disease progression within the first 6 months of abiraterone actetate at standard dose (1000 mg/d) and have a plasma abiraterone concentration below 8.5 ng/mL. It is a non-comparative phase 2 study in which patients will be included in two successive steps. Patients with mCRPC will be included in the first step and treated with standard dose (1000 mg/day) of ABI + prednisone /prednisolone (10 mg/d) according to the summary of product characteristics and monitored for trough ABI plasma level each month for 3 months. In the second step intrapatient ABI dose escalation (2000 mg/day) + prednisone/prednisolone (10 mg/d) will be realized for patients from the first step experiencing progressive disease within 6 months of ABI standard dose and with mean ABI plasma level during the first three months < 8.5 ng/mL
Status | Completed |
Enrollment | 94 |
Est. completion date | December 27, 2021 |
Est. primary completion date | April 29, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Step 1 - Male 18 years and older. - Voluntary signed informed consents of the patient before any study-specific procedure. - Histologically confirmed prostate adenocarcinoma. - Presence of bone and/or soft-tissue and/or visceral metastases through CT scan, MRI, scintigraphy scan. - Progressive disease assessed by PSA, CT scan, MRI or bone scan according to the PCGW3 criteria PSA progression is defined as a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir, which is confirmed by a second value obtained 1 or more weeks later. Bone scan: at least two or more new lesions are seen on bone scan compared with a prior scan. - Patient with no or moderate symptoms (no need for continuous opioid treatment) - Effective castration confirmed by testosterone plasma level < 50 ng/dL - ECOG performance status: 0-2 - Life expectancy > 3 months - Patient affiliate to french social assurance - Laboratory criteria within 14 days before inclusion: - SGPT and SGOT < 5 fold the upper normal value - Kaliemia > 3 mM - Patient using an effective contraceptive method during treatment Step2 - Patients receiving ABI 1000 mg/day + prednisone/prednisolone 10 mg once a day through step 1 for at least two months - At least two measures of ABI plasma concentrations available within the first three months of treatment - Mean of ABI concentration < 8,5 ng/mL. - Progressive disease occuring within 28 weeks following starting of ABI in the step 1. A progressive disease is assessed by PSA increase or bone scan according to PCWG3 criteria (15) or to CT scan according to RECIST 1.1 criteria (see ยง 2). - Inclusion in step 2 must occur within 2 months following the first observation of cancer progression while in step 1. - Patient using an effective contraceptive method during treatment Exclusion Criteria: Step 1 - Pure small cell carcinoma of the prostate or predominant histology of neuro-endocrine carcinoma. - Confirmed brain and/or leptomeningeal metastases - Previous treatment with docetaxel or any other anticancer treatment for castration-resistant prostate carcinoma (previous docetaxel for hormone-sensitive metastatic disease is allowed) - Previous treatment with ABI or any other 17 B hydroxylase inhibitor or enzalutamide - Treatment with first-generation antiandrogen (ciproterone acetate, bicalutamide, flutamide, nilutamide) performed on the day of baseline or within previous four weeks, due to possible anti-androgen withdrawal response. (This criterion does not apply for subjects, who have never responded to anti-androgen treatment). - Patient co-morbidities: - Patients with the following hereditary diseases: galactose hypersensitivity, Lapp lactase deficiency. - Cirrhosis Child-Pugh B or C - Active or symptomatic viral hepatitis - Heart failure stage NYHA III or IV - Cardiac arythmia, heart failure stage NYHA II, ischemic cardiopathy or uncontroled hypertension, except if left ventricular ejection fraction is > 50% - Patients with left ventricular ejection fraction (LVEF) < 50% - Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.Prior or concurrent malignant disease in complete remission for less than 3 years, except T1N0 vocal cord carcinoma, basal or squamous cell skin carcinoma and in situ transitional cell bladder carcinoma - Limitation of the patient's ability to comply with the treatment or to follow-up the protocol. Step 2 Grade 3-4 toxicities related to ABI. In case of persistent grade 2 toxicity, inclusion in step 2 must be discussed in a case by case basis with the study coordinating Investigator. - All non-inclusion criteria for step 1 applied - Patient who is not adherent to ABI treatment at the investigator opinion - Patient with a symptomatic and/or visceral tumor progression that would be an indication to start chemotherapy immediately according to the opinion of the investigator |
Country | Name | City | State |
---|---|---|---|
France | Department of Medical Oncology, Cochin Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Janssen, LP |
France,
Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NE, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2017 Feb;72:54-61. doi: 10.1016/j.ejca.2016.11.027. Epub 2016 Dec 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-progression rate | The proportion of patients who do not experience progressive disease (defined by PSA and/or radiographic progression) among those receiving ABI at a dose of 2000 mg / day + prednisone/prednisolone after failure of standard dose (1000 mg/day). | 12 weeks | |
Secondary | Incidence of underexposure to ABI | Incidence of underexposure to ABI (mean plasma concentration < 8.5 ng/mL) in patients treated at standard dose (1000 mg / day) and identification of inter- and intra-individual variability factors of plasma levels of ABI | 3 months | |
Secondary | Evaluation of adherence to ABI and correlation with mean plasma ABI concentration | The adherence will be evaluated using two tools: the french version of the Girerd survey filled by the patient at 12 weeks and a personal treatment log book indicating daily times of drug administration | 3 months | |
Secondary | Evaluation of adherence to ABI and correlation with mean plasma ABI concentration | The adherence will be evaluated using two tools: the french version of the Girerd survey filled by the patient at 24 weeks and a personal treatment log book indicating daily times of drug administration | 6 months | |
Secondary | PSA response rate in patients treated at escalated dose | PSA response rate is defined as the proportion of patients with a decrease of = 50% in the PSA concentration from the pretreatment baseline value, confirmed after = 3 weeks by an additional PSA evaluation | 6 months | |
Secondary | Progression free survival in patients treated at escalated dose | Time from inclusion to progression or death in patients treated at escalated dose Disease progression is defined as either PSA or radiologic progression as described above | 6 months | |
Secondary | Incidence of adverse events related to ABI at a dose of 2000 mg/day according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |